, Volume 15, Issue 12, pp 594–604 | Cite as

Prolifération des cancers du sein et biomarqueurs décisionnels en pratique RPC (RPC 2013)

  • F. André
  • S. Delaloge
  • J. -M. Guinebretière
  • T. Petit
  • J. -Y. Pierga
  • D. Zarca
  • K. Zarca
Recommandations / Guidelines


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Albain KS, Barlow WE, Shak S, et al. (2010) Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 11(1): 55–65PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100(7): 3983–3988PubMedCrossRefGoogle Scholar
  3. 3.
    Azim Jr HA, Michiels S, Bedard PL, et al. (2012) Biology of breast cancer diagnosed in young women: pooled gene expression analysis from 3,522 patients. Ann Oncol 23(Suppl 2): ii19 (140-PR)Google Scholar
  4. 4.
    Barton S, Zabaglo L, A’Hern R, et al. (2012) Assessment of the contribution of the IHC4+C score to decision-making in clinical practice in early breast cancer. Br J Cancer 106(11): 1760–1765PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Beresford MJ, Stott D, Makris A (2008) Assessment of clinical response after two cycles of primary chemotherapy in breast cancer. Breast Cancer Res Treat 109(2): 337–342PubMedCrossRefGoogle Scholar
  6. 6.
    Berruti A, Generali D, Kaufmann M, et al. (2011) International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). J Natl Cancer Inst Monogr (43): 147–151CrossRefGoogle Scholar
  7. 7.
    Blohmer JU, Rezai M, Kummel S, et al. (2013) Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting. J Med Econ 16(1): 30–40PubMedCrossRefGoogle Scholar
  8. 8.
    Bullwinkel J, Baron-Luhr B, Ludemann A, et al. (2006) Ki-67 protein is associated with ribosomal RNA transcription in quiescent and proliferating cells. J Cell Physiol 206(3): 624–635PubMedCrossRefGoogle Scholar
  9. 9.
    Buyse M, Loi S, van’t Veer L, et al. (2006) Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98(17): 1183–1192PubMedCrossRefGoogle Scholar
  10. 10.
    Cheang MC, Chia SK, Voduc D, et al. (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101(10): 736–750PubMedCrossRefGoogle Scholar
  11. 11.
    Coudert B, Asselain B, Campone M, et al. (2012) Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial. Oncologist 17(7): 900–909PubMedCrossRefGoogle Scholar
  12. 12.
    Cronin M, Sangli C, Liu ML, et al. (2007) Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin Chem 53(6): 1084–1091PubMedCrossRefGoogle Scholar
  13. 13.
    Cuzick J, Dowsett M, Pineda S, et al. (2011) Prognostic value of a combined estrogen receptor, progesterone receptor, Ki67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer. J Clin Oncol 29(32): 4273–4278PubMedCrossRefGoogle Scholar
  14. 14.
    Daidone MG, Silvestrini R (2001) Prognostic and predictive role of proliferation indices in adjuvant therapy of breast cancer. J Natl Cancer Inst Monogr 30: 27–35PubMedCrossRefGoogle Scholar
  15. 15.
    Ding L, Ellis MJ, Li S, et al. (2010) Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464(7291): 999–1005PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Dowsett M, Nielsen TO, A’Hern R, et al. (2011) Assessment of Ki67 in breast cancer: recommendations from the international Ki67 in breast cancer working group. J Natl Cancer Inst 103(22): 1656–1664PubMedCrossRefGoogle Scholar
  17. 17.
    Dowsett M, Smith IE, Ebbs SR, et al. (2007) Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 99(2): 167–170PubMedCrossRefGoogle Scholar
  18. 18.
    Dumontet C, Krajewska M, Treilleux I, et al. (2010) BCIRG 001 molecular analysis: prognostic factors in node-positive breast cancer patients receiving adjuvant chemotherapy. Clin Cancer Res 16(15): 3988–3997PubMedCrossRefGoogle Scholar
  19. 19.
    Ellis MJ, Tao Y, Luo J, et al. (2008) Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 100(19): 1380–1388PubMedCrossRefGoogle Scholar
  20. 20.
    Filipits M, Rudas M, Jakesz R, et al. (2011) A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res 17(18): 6012–6020PubMedCrossRefGoogle Scholar
  21. 21.
    Gerdes J, Schwab U, Lemke H, Stein H (1983) Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31(1): 13–20PubMedCrossRefGoogle Scholar
  22. 22.
    Gerlinger M, Rowan A, Horswell S, et al. (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366(10): 883–892PubMedCrossRefGoogle Scholar
  23. 23.
    Gokmen-Polar Y, Badve S (2012) Molecular profiling assays in breast cancer: are we ready for prime time? Oncology (Williston Park) 26(4): 350–357, 61Google Scholar
  24. 24.
    Goldhirsch A, Wood WC, Coates AS, et al. (2011) Strategies for subtypes —ealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22(8): 1736–1747PubMedCrossRefGoogle Scholar
  25. 25.
    Guiu S, Michiels S, Andre F, et al. (2012) Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. Ann Oncol 23(12): 2997–3006PubMedCrossRefGoogle Scholar
  26. 26.
    Habashy HO, Powe DG, Abdel-Fatah TM, et al. (2012) A review of the biological and clinical characteristics of luminal-like oestrogen receptor-positive breast cancer. Histopathology 60(6): 854–863PubMedCrossRefGoogle Scholar
  27. 27.
    Hall PS, McCabe C, Stein RC, Cameron D (2012) Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer. J Natl Cancer Inst 104(1): 56–66PubMedCrossRefGoogle Scholar
  28. 28.
    Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5): 646–674PubMedCrossRefGoogle Scholar
  29. 29.
    Harris L, Fritsche H, Mennel R, et al. (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25(33): 5287–5312PubMedCrossRefGoogle Scholar
  30. 30.
    Henry LR, Stojadinovic A, Swain SM, et al. (2009) The influence of a gene expression profile on breast cancer decisions. J Surg Oncol 99(6): 319–323PubMedCrossRefGoogle Scholar
  31. 31.
    Heppner G (1984) Tumor heterogeneity. Cancer Res 44: 2259–2265PubMedGoogle Scholar
  32. 32.
    Hugh J, Hanson J, Cheang MC, et al. (2009) Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 27(8): 1168–1176PubMedCrossRefGoogle Scholar
  33. 33.
    Jankowitz RC, Cooper K, Erlander MG, et al. (2011) Prognostic utility of the breast cancer index and comparison to adjuvant! Online in a clinical case series of early breast cancer. Breast Cancer Res 13(5): R98PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Jerevall PL, Ma XJ, Li H, et al. (2011) Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial. Br J Cancer 104(11): 1762–1769PubMedCentralPubMedCrossRefGoogle Scholar
  35. 35.
    Jones RL, Salter J, A’Hern R, et al. (2009) The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 116(1): 53–68PubMedCrossRefGoogle Scholar
  36. 36.
    Kelly CM, Warner E, Tsoi DT, et al. (2010) Review of the clinical studies using the 21-gene assay. Oncologist 15(5): 447–456PubMedCrossRefGoogle Scholar
  37. 37.
    Klang SH, Hammerman A, Liebermann N, et al. (2010) Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health care organization. Value Health 13(4): 381–387PubMedCrossRefGoogle Scholar
  38. 38.
    Knauer M, Cardoso F, Wesseling J, et al. (2010) Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature. Br J Cancer 103(12): 1788–1793PubMedCentralPubMedCrossRefGoogle Scholar
  39. 39.
    Kondo M, Hoshi SL, Yamanaka T, et al. (2011) Economic evaluation of the 21-gene signature (Oncotype DX) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03). Breast Cancer Res Treat 127(3): 739–749PubMedCrossRefGoogle Scholar
  40. 40.
    Kronenwett R, Bohmann K, Prinzler J, et al. (2012) Decentral gene expression analysis: analytical validation of the Endopredict_genomic multianalyte breast cancer prognosis test. BMC Cancer 12: 456PubMedCentralPubMedCrossRefGoogle Scholar
  41. 41.
    Laas E, Vataire AL, Aballea S, et al. (2012) Evaluation of the costs and resource use associated with adjuvant chemotherapy for breast cancer in France. J Med Econ 15(6): 1167–1175PubMedCrossRefGoogle Scholar
  42. 42.
    Lamond NW, Skedgel C, Rayson D, et al. (2012) Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer. Breast Cancer Res Treat 133(3): 1115–1123PubMedCrossRefGoogle Scholar
  43. 43.
    Lo SS, Mumby PB, Norton J, et al. (2010) Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol 28(10): 1671–1676PubMedCrossRefGoogle Scholar
  44. 44.
    Loi S, Haibe-Kains B, Desmedt C, et al. (2007) Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 25(10): 1239–1246PubMedCrossRefGoogle Scholar
  45. 45.
    Luporsi E, Andre F, Spyratos F, et al. (2012) Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat 132(3): 895–915PubMedCentralPubMedCrossRefGoogle Scholar
  46. 46.
    Mackey JR, Martin M, Pienkowski T, et al. (2013) Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol 14(1): 72–80PubMedCrossRefGoogle Scholar
  47. 47.
    Metzger Filho O, Ignatiadis M, Sotiriou C (2011) Genomic Grade Index: an important tool for assessing breast cancer tumor grade and prognosis. Crit Rev Oncol Hematol 77(1): 20–29PubMedCrossRefGoogle Scholar
  48. 48.
    Mook S, Schmidt MK, Viale G, et al. (2009) The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1–3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat 116(2): 295–302PubMedCrossRefGoogle Scholar
  49. 49.
    Navin N, Kendall J, Troge J, et al. (2011) Tumour evolution inferred by single-cell sequencing. Nature 472(7341): 90–94PubMedCrossRefGoogle Scholar
  50. 50.
    Nielsen TO, Parker JS, Leung S, et al. (2010) A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 16(21): 5222–5232PubMedCentralPubMedCrossRefGoogle Scholar
  51. 51.
    Nik-Zainal S, Van Loo P, Wedge DC, et al. (2012) The life history of 21 breast cancers. Cell 149(5): 994–1007PubMedCentralPubMedCrossRefGoogle Scholar
  52. 52.
    Paik S, Shak S, Tang G, et al. (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27): 2817–2826PubMedCrossRefGoogle Scholar
  53. 53.
    Paik S, Tang G, Shak S, et al. (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24(23): 3726–3734PubMedCrossRefGoogle Scholar
  54. 54.
    Parker JS, Mullins M, Cheang MC, et al. (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27(8): 1160–1167PubMedCrossRefGoogle Scholar
  55. 55.
    Penault-Llorca F, Goubar A, Raoelfils I, et al. (2012) Interpathologists discrepancies in Ki67 assessment in the PACS01 trial: an independent prognosis factor. J Clin Oncol 30(Suppl); abstr 543Google Scholar
  56. 56.
    Penault-Llorca F, Andre F, Sagan C, et al. (2009) Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. J Clin Oncol 27(17): 2809–2815PubMedCrossRefGoogle Scholar
  57. 57.
    Perou CM, Jeffrey SS, van de Rijn M, et al. (1999) Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA 96(16): 9212–9217PubMedCrossRefGoogle Scholar
  58. 58.
    Perou CM, Sorlie T, Eisen MB, et al. (2000) Molecular portraits of human breast tumours. Nature 406(6797): 747–752PubMedCrossRefGoogle Scholar
  59. 59.
    Regan MM, Neven P, Giobbie-Hurder A, et al. (2011) Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1–98 randomised clinical trial at 8.1 years median follow-up. Lancet Oncol 12(12): 1101–1108PubMedCentralPubMedCrossRefGoogle Scholar
  60. 60.
    Sheri A, Dowsett M (2012) Developments in Ki67 and other biomarkers for treatment decision-making in breast cancer. Ann Oncol 23(Suppl 10): x219–x227PubMedCrossRefGoogle Scholar
  61. 61.
    Simon RM, Paik S, Hayes DF (2009) Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101(21): 1446–1452PubMedCrossRefGoogle Scholar
  62. 62.
    Sorlie T, Perou CM, Tibshirani R, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19): 10869–10874PubMedCrossRefGoogle Scholar
  63. 63.
    Sotiriou C, Neo SY, McShane LM, et al. (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100(18): 10393–10398PubMedCrossRefGoogle Scholar
  64. 64.
    Sotiriou C, Wirapati P, Loi S, et al. (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98(4): 262–272PubMedCrossRefGoogle Scholar
  65. 65.
    Stadler ZK, Come SE (2009) Review of gene-expression profiling and its clinical use in breast cancer. Crit Rev Oncol Hematol 69(1): 1–11PubMedCrossRefGoogle Scholar
  66. 66.
    Stephens PJ, Tarpey PS, Davies H, et al. (2012) The landscape of cancer genes and mutational processes in breast cancer. Nature 486(7403): 400–404PubMedCentralPubMedGoogle Scholar
  67. 67.
    Tang G, Cuzick J, Costantino JP, et al. (2011) Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors. J Clin Oncol 29(33): 4365–4372PubMedCrossRefGoogle Scholar
  68. 68.
    Teutsch SM, Bradley LA, Palomaki GE, et al. (2009) The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med 11(1): 3–14PubMedCentralPubMedCrossRefGoogle Scholar
  69. 69.
    Urruticoechea A, Smith IE, Dowsett M (2005) Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 23(28): 7212–7220PubMedCrossRefGoogle Scholar
  70. 70.
    van de Vijver MJ, He YD, van’t Veer LJ, et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347(25): 1999–2009PubMedCrossRefGoogle Scholar
  71. 71.
    van Diest PJ, van der Wall E, Baak JP (2004) Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol 57(7): 675–681PubMedCrossRefGoogle Scholar
  72. 72.
    van’t Veer LJ, Dai H, van de Vijver MJ, et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871): 530–536CrossRefGoogle Scholar
  73. 73.
    Varga Z, Diebold J, Dommann-Scherrer C, et al. (2012) How reliable is Ki-67 immunohistochemistry in grade II breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists. PLoS ONE 7(5): e37379PubMedCentralPubMedCrossRefGoogle Scholar
  74. 74.
    Vataire AL, Laas E, Aballea S, et al. (2012) Cost-effectiveness of a chemotherapy predictive test. [Article in French] Bull Cancer 99(10): 907–914PubMedGoogle Scholar
  75. 75.
    Viale G, Giobbie-Hurder A, Regan MM, et al. (2008) Prognostic and predictive value of centrally reviewed Ki-67 labelling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1–98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 26(34): 5569–5575PubMedCrossRefGoogle Scholar
  76. 76.
    Viale G, Regan MM, Mastropasqua MG, et al. (2008) Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst 100(3): 207–212PubMedCrossRefGoogle Scholar
  77. 77.
    Visvader JE, Lindeman GJ (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8(10): 755–768PubMedCrossRefGoogle Scholar
  78. 78.
    von Minckwitz G, Untch M, Loibl S (2013) Update on neoadjuvant/preoperative therapy of breast cancer: experiences from the German Breast Group. Curr Opin Obstet Gynecol 25(1): 66–73CrossRefGoogle Scholar
  79. 79.
    Weigel MT, Dowsett M (2010) Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Relat Cancer 17(4): R245–R262PubMedCrossRefGoogle Scholar
  80. 80.
    Yang M, Rajan S, Issa AM (2012) Cost effectiveness of gene expression profiling for early-stage breast cancer: a decision-analytic model. Cancer 118(20): 5163–5170PubMedCrossRefGoogle Scholar
  81. 81.
    Yerushalmi R, Woods R, Ravdin PM, et al. (2010) Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 11(2): 174–183PubMedCrossRefGoogle Scholar

Références électroniques

  1. 82.
    Collège des économistes de la santé (2008) Guide méthodologique pour la mise en place d’une analyse d’impact budgétaire. Available from: http://www.ces-asso.org/docs/Rapport_AIB.pdf Google Scholar
  2. 83.
    Haute Autorité de santé (2011) Choix méethodologiques pour l’éevaluation économique à la HAS. Available from: http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-11/guide_methodo_vf.pdf Google Scholar
  3. 84.
    Orphanet. Hémoglobinurie paroxystique nocturne 2012. Available from: http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=FR&Expert=447.
  4. 85.
    SOLIRIS 300MG/30ML SOL INJ FL 30ML —Monographie specialité. 2012. Available from: http://www.theriaque.org/apps/monographie/index.php?type=SP&id=21952&info=ADMIN

Copyright information

© Springer-Verlag France 2013

Authors and Affiliations

  • F. André
    • 1
  • S. Delaloge
    • 1
  • J. -M. Guinebretière
    • 2
  • T. Petit
    • 3
  • J. -Y. Pierga
    • 4
  • D. Zarca
    • 5
  • K. Zarca
    • 6
  1. 1.oncologue médicalVillejuifFrance
  2. 2.anatomo-pathologisteSaint-CloudFrance
  3. 3.oncologue médicalStrasbourgFrance
  4. 4.oncologue médicalParisFrance
  5. 5.gynécologueParisFrance
  6. 6.médecin de Santé PubliqueParisFrance

Personalised recommendations